PRA Health Sciences — Q4 2014 Earnings Presentation
13 slides from PRA Health Sciences's earnings presentation, Feb 18, 2015
Slide 1: Q4 2014 Earnings
Q4 2014 Earnings February 18, 2015
Slide 2: Forward Looking Statements and Use of Non-GAAP Financial Measures
Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking statements that reflect, among other things, the Company’s current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and o
Slide 3: Q4 and FY 2014 Financial Results
Q4 and FY 2014 Financial Results ($ in millions) Q4 2014 Q4 2013 % Change FY 2014 FY 2013 % Change Service Revenue 323.8 $ 298.8 $ 8.4% 1,266.6 $ 832.9 $ 52.1% EBITDA 17.4 $ 21.0 $ -17.1% 134.6 $ (20.7) $ -750.2% Adjusted EBITDA 50.6 $ 35.3 $ 43.3% 182.8 $ 130.6 $ 40.0% Adjusted EBITDA Margin 15.6%
Slide 4: Trailing Quarterly Performance
Trailing Quarterly Performance FY 14 v ($ in millions) FY 13 % Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Change Service revenue 166.5 $ 179.5 $ 188.1 $ 298.8 $ 832.9 $ 311.4 $ 311.3 $ 320.1 $ 323.8 $ 1,266.6 $ 52.1% % growth Y-o-Y 13.0% 22.2% 27.9% 91.7% 39.5% 87.0% 73.4% 70.2% 8.4% 52.1% % growth Y-o-Y (consta
Slide 5: Backlog and New Business Awards
Backlog and New Business Awards FY 14 v ($ in millions) FY 13 % Q1 Q2 Q3 Q4 FY Q1 Q2 Q3 Q4 FY Change Beginning Backlog 1,382.8 $ 1,421.2 $ 1,444.2 $ 1,465.6 $ 1,382.8 $ 1,939.7 $ 1,987.3 $ 2,044.8 $ 2,091.5 $ 1,939.7 $ Ending Backlog 1,421.2 $ 1,444.2 $ 1,465.6 $ 1,939.7 $ 1,939.7 $ 1,987.3 $ 2,044.
Slide 6: Debt Structure
Debt Structure Weighted Average ($ in millions) December 31, March 31, June 30, September 30, December 31, Interest Maturity 2013 2014 2014 2014 2014 Rate Date Senior debt: First Lien 887.8 $ 885.6 $ 883.3 $ 881.1 $ 729.0 $ 4.50% September 23, 2020 Senior Notes 375.0 375.0 375.0 375.0 225.0 9.50% Oc
Slide 7: Reconciliation of GAAP EBITDA to Adjusted EBITDA
Reconciliation of GAAP EBITDA to Adjusted EBITDA For further information regarding the reconciliation of non-GAAP measures to their corresponding GAAP equivalent please see our press release Twelve Twelve Months Months Ended Ended ($ in millions) December 31, December 31, 2014 2013 2014 2013 Net los
Slide 8: Reconciliation of GAAP Net Loss to Adjusted Net Income
Reconciliation of GAAP Net Loss to Adjusted Net Income For further information regarding the reconciliation of non-GAAP measures to their corresponding GAAP equivalent please see our press release Twelve Twelve Months Months Ended Ended ($ in millions, except per share datat) December 31, December 3
Slide 9: Reconciliation of GAAP Income (Loss) from Operations to Adjusted Income from Operations
Reconciliation of GAAP Income (Loss) from Operations to Adjusted Income from Operations For further information regarding the reconciliation of non-GAAP measures to their corresponding GAAP equivalent please see our press release Twelve Twelve Months Months Ended Ended ($ in millions) December 31, D
Slide 10: Appendix
Appendix RAHEALTHSCIEN.
Slide 11: Geographic Breakdown
Geographic Breakdown Region Q4 14 Q4 13 US/Canada $ 193.4 $ 175.0 Europe/Africa 102.9 100.5 Latin America 13.4 13.4 Asia/Pacific 14.1 9.9 Total Service Revenue $ 323.8 $ 298.8 Region FY 2014 FY 2013 US/Canada $ 755.5 $ 438.9 Europe/Africa 402.7 341.1 Latin America 54.0 26.5 Asia/Pacific 54.4 26.4 To
Slide 12: Days Sales Outstanding
Days Sales Outstanding ($ in millions) Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Accounts Receivable, net 136.9 $ 157.4 $ 141.2 $ 232.6 $ 246.0 $ 241.9 $ 236.1 $ 233.2 $ Unbilled Services 63.1 56.2 58.3 62.3 102.3 98.0 113.2 105.5 Total Accounts Receivable and Unbilled Services 200.0 213.6 199.5 294.9 348.3 339.9 349
Slide 13: siz
siz OS PRAHEALTHSCIENCES HEF URE OF CLINICAL DEVELOPMEN